NIS to examine the effectiveness and safety of durvalumab and olaparib in patients with endometrial cancer (DUOLife)

Trial Identifier:	D9311R00001
Sponsor:	AstraZeneca
Collaborator:	North-Eastern German Society of Gynecological Oncology (NOGGO e.V.)
Start Date:	March 2025
Primary Completion Date:	September 2028
Study Completion Date:	September 2028
Condition:	Endometrial Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.